Table 3.
Continuous BPV | T1 | T2 | T3 | ||||
---|---|---|---|---|---|---|---|
N | 16,193 | 5,398 | 5,430 | 5,365 | |||
Estimatea | Interactionb | Estimatea | Interactionb | Estimatea | Interactionb | ||
Model 1 | −0.18 (P < 0.01) |
−0.01 (P = 0.08) |
REF | −0.34 (P = 0.21) |
0.02 (P = 0.73) |
−2.23 (P < 0.01) |
−0.04 (P = 0.54) |
Model 2 | −0.12 (P < 0.01) |
−0.01 (P = 0.09) |
REF | −0.05 (P = 0.85) |
0.02 (P = 0.75) |
−1.44 (P < 0.01) |
−0.04 (P = 0.55) |
Model 3 | −0.11 (P < 0.01) |
−0.01 (P = 0.10) |
REF | −0.02 (P = 0.94) |
0.02 (P = 0.76) |
−1.29 (P < 0.01) |
−0.04 (P = 0.56) |
Model 4 | −0.10 (P < 0.01) |
−0.01 (P = 0.10) |
REF | 0.01 (P = 0.96) |
0.02 (P = 0.76) |
−1.21 (P < 0.01) |
−0.04 (P = 0.56) |
Model 5 | −0.08 (P < 0.01) |
−0.01 (P = 0.11) |
REF | 0.11 (P = 0.68) |
0.02 (P = 0.75) |
−0.90 (P < 0.01) |
−0.04 (P = 0.57) |
Abbreviations: BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; REF, reference. Model 1: unadjusted. Model 2: adjusted for age and sex. Model 3: includes Model 2 adjustments and diabetes, smoking, country, aspirin, race/ethnicity, BMI, and baseline statin use. Model 4: includes Model 3 adjustments and within-individual mean systolic blood pressure from baseline to second annual visit. Model 5: includes Model 4 adjustments and baseline antihypertensive drug use.
aEstimate of the cross-sectional association of BPV with eGFR at baseline.
bTime–BPV interaction term to test variation of the eGFR trajectory among BPV levels.